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Objective: To examine whether plasma neurofilament light (NFL)
might be a potential longitudinal biomarker for Alzheimer’s disease
(AD).
Methods: A total of 835 individuals from the Alzheimer’s Disease
Neuroimaging Initiative were involved. Correlations of the rate of
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change in plasma NFL with cerebrospinal fluid biomarkers, cognition,
and brain structure were investigated. Cox proportional hazards models
were used to assess the associations between quartiles of plasma NFL
and the risk of AD conversion.
Results: Participants were further divided into β amyloid-positive
(Aβ+) versus β amyloid-negative (Aβ−), resulting in five biomarker
group combinations, which are CN Aβ−, CN Aβ+, MCI Aβ−, MCI
Aβ+ and AD Aβ+. Plasma NFL concentration markedly increased in
the five groups longitudinally ( p < 0.001) with the greatest rate of
change in AD Aβ+ group. The rate of change in plasma NFL was
associated with cognitive deficits and neuroimaging hallmarks of
AD over time (p < 0.005). Compared with the bottom quartile, the
top quartile of change rate was associated with a 5.41-fold increased
risk of AD (95% CI = 1.83−16.01) in the multivariate model.
Conclusion: Our finding implies the potential of plasma NFL as a
longitudinal noninvasive biomarker in AD.

Introduction

Alzheimer’s disease (AD) is a common neurodegenerative disease which is characterized by
brain accumulation of β-amyloid (Aβ) and tau,
progressive atrophy, and cognitive decline [1].

Biomarkers that capture biological processes in
AD are increasingly used to support the diagnosis
of AD in research and clinical practice [2, 3]. The
most well-established AD biomarkers include
cerebrospinal fluid (CSF) biomarkers of Aβ, tau,
and neurodegeneration / neuronal injury, positron
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emission tomographic (PET) imaging of Aβ, tau,
and brain metabolism, as well as structural
magnetic resonance imaging (MRI) [4−6]. The
application of these biomarkers is hampered by a
high degree of invasiveness, high cost, or limited
availability [7]. Therefore, there is a strong need
to develop blood-based biomarkers that, when
applied in a proper context of use, could serve
as relative noninvasive screening tests.
Neurofilament light (NFL), a neuronal injury
marker, is one of the potential blood-based
biomarkers for AD [8, 9]. NFLs are neuron-specific
heteropolymers that act as key structural components of the neuronal cytoskeleton and are
mostly expressed in large-caliber myelinated axons
[10]. Axonal damage leads to the release of NFL
molecules into the extracellular space and consequently into body fluids, including CSF and
plasma [11]. In line with this, increased blood
NFL concentrations were reported in neurodegenerative and neuro-inflammatory disorders
[12, 13], including AD [1, 14]. Previous studies
have validated that baseline plasma NFL concentration is increased in AD patients [11, 15] and
it correlates with impaired cognition, neuroimaging
abnormalities, and CSF biomarkers of AD
pathologic features [16]. These evidences suggest
that plasma NFL might be a promising peripheral
biomarker for AD. However, this analysis was
based on the baseline concentration of plasma
NFL. A recent study analyzed the longitudinal
change in serum NFL and found that it predicted
neurodegeneration and clinical progression in presymptomatic familial AD [17]. However, studies
using NFL in plasma as a longitudinal noninvasive
proxy for neurodegeneration in sporadic AD are
rare.
Herein, based on the longitudinal data gathered
from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) prospective cohort, we calculated
the rate of change in plasma NFL and tested the
hypothesis that it correlates with cognitive,

http://bsa.tsinghuajournals.com

biochemical, and imaging hallmarks of AD.

2

Materials and methods

2.1 Participants
Data used in the preparation for this article
were obtained from the ADNI database (http://
adniloni.usc.edu) [18, 19], which was led by
Principal Investigator Michael W. Weiner, MD.
ADNI is a multisite longitudinal biomarker study
that to date has enrolled over 1,800 cognitively
normal (CN), amnestic mild cognitive impairment
(MCI), and AD individuals, aged from 55 to
90 years old. Participants received baseline and
periodic physical and neurological examinations
as well as standardized neuropsychological
assessments, and provided biological samples
(blood, urine, CSF, etc.) throughout the study.
Imaging (MRI and PET) is performed at baseline
and at regular intervals thereafter. Informed
consent was obtained from study participants, and
the study was approved by the local institutional
review board at each participating site. Our study
population consisted of all CN, MCI, and AD
dementia participants with available plasma NFL,
CSF biomarker, cognitive and imaging data.
Inclusion and exclusion criteria are described in
detail online (http://www.adni-info.org).
2.2 Plasma NFL
Plasma NFL was examined by the Single Molecule
array (Simoa) technique. The assay uses a combination of monoclonal antibodies, and purified
bovine NFL as a calibrator. All samples were
measured in duplicate. Analytical sensitivity was
< 1.0 pg/mL. Values are presented as pg/mL.
Further information about the methods can be
found at adni.loni.usc.edu.
2.3 CSF measurements
CSF was sampled by lumbar puncture from a
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subset of participants, with CSF Aβ, CSF total
tau (T-tau), and CSF phosphorylated tau (P-tau)
measured using a multiplex platform (xMAP;
Luminex Corporation) with a kit (INNO-BIA
AlzBio3; Fujirebio Europe).
2.4 Cognition
Cognition was assessed by Mini-Mental State
Examination (MMSE), Clinical Dementia Rating
Sum of Boxes (CDRSB) and Alzheimer Disease
Assessment Scale-cognitive subscale (ADAS-cog
11 and 13). All tests were administered at baseline
and follow-up.
2.5 Neuroimaging
Structural brain images were acquired using
1.5-T MRI imaging system with T1-weighted MRI
scans using a sagittal volumetric magnetizationprepared rapid acquisition gradient-echo sequence.
A software program (FreeSurfer; https://
surfer.nmr.mgh.harvard.edu/) was used for quantification of cortical thickness and subcortical
volumes. We used volumetric data for entorhinal
cortex (EC) thickness and hippocampal volume
(HV).
2.6 Statistical analysis
Based on the cut-off threshold of CSF Aβ [15, 20],
we dichotomized the population, resulting in
five different biomarker group combinations,
including CN Aβ− (CN−), CN Aβ+ (CN+), MCI
Aβ− (MCI−), MCI Aβ+ (MCI+) and AD Aβ+ (AD+).
Tests of inter-group differences were performed
using one-way analysis of variance and post-hoc
analysis. Categorical variables are presented as
number (percentage); continuous variables as
mean ± standard deviation (SD). The longitudinal
rate of change in plasma NFL, CSF biomarkers,
cognition and brain structure were calculated by
linear mixed-effects models. Associations between
rate of change in plasma NFL and CSF biomarkers /

subsequent disease progression (measured by
MMSE, CDRSB, ADAS-cog scores, EC thickness
and HV atrophy) were tested using linear mixedeffects models adjusted for age and sex (and
educational level for cognitive measurements, and
intracranial volume for volume measurements).
All outcome variables in linear mixed-effects
models were log-transformed to facilitate comparisons between modalities. Baseline plasma
NFL and rate of change in plasma NFL were
quartered. Kaplan-Meier analysis with log-rank
test to determine the progression from CN to
prodromal AD (defined as CDRSB score ≥ 0.5)
and that from MCI to AD were performed. Time
to event was defined as time from baseline CN
to prodromal AD and that from MCI to AD onset
(with end of study time or dropout as censoring).
Multi-adjusted Cox proportional hazard regression
models adjusted for age, sex and educational level
and additional adjustment for APOE ε4 status
were performed. We also calculated diagnostic
accuracies using area under the receiver operating
characteristic curve (AUROC) analysis with 10-fold
cross-validated logistic regression models.
All tests were 2-sided and statistical significance
was set at p < 0.05. All statistical analyses were
performed using a software program (R, version
3.5.1) and IBM SPSS Statistics 23.

3

Results

The present analysis involved 835 participants,
including 178 CN−, 113 CN+, 168 MCI−, 290 MCI+,
and 86 AD+ individuals. Characteristics of
participants in the final data set are presented in
Table 1 (female percentage: 45.9%; age: 72.53 ±
7.02 years old; years of education: 16.23 ± 2.66;
and percentage of APOE ε4 positive: 43.5%). At
baseline, high plasma NFL levels were associated
with lower CSF Aβ (Spearman correlation β =
−0.295, p < 0.001), elevated CSF P-tau (β = 0.210,
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Table 1 Basic characteristics of population included
Characteristics

CN−

CN+

MCI−

MCI+

AD+

Number of participants

178

113

168

290

86

Age (years)

72.70 ± 5.84

74.64 ± 6.05

70.17 ± 7.69

72.50 ± 7.02

74.09 ± 7.86

Female gender

90 (50.6%)

62 (54.9%)

81 (48.2%)

114 (39.3%)

36 (41.9%)

Education (years)

16.58 ± 2.72

16.34 ± 2.37

16.21 ± 2.60

16.13 ± 2.78

15.69 ± 2.57

APOE ε4 carriers

27 (15.1%)

49 (43.4%)

33 (19.6%)

191 (65.9%)

64 (74.4%)

MMSE

29.06 ± 1.21*#$

29.04 ± 1.14*#$

28.46 ± 1.49#$§¶

27.68 ± 1.80*$§¶

23.15 ± 1.97*#§¶

CDRSB

0.04 ± 0.13*#$

0.05 ± 0.17*#$

1.26 ± 0.75#$§¶

1.57 ± 0.92*$§¶

4.53 ± 1.66*#§¶

ADAS-cog 11

5.54 ± 2.74

5.81 ± 3.08

7.93 ± 3.01

*$§¶

10.40 ± 4.60

20.80 ± 6.95*#§¶

ADAS-cog 13

8.46 ± 4.08*#$

9.40 ± 4.48*#$

12.96 ± 5.28#$§¶

16.96 ± 6.72*$§¶

31.28 ± 8.17*#§¶

EC thickness (mm)

3861.30 ± 645.55#$

3888.86 ± 548.54#$

3766.57 ± 679.61#$

3546.03 ± 721.48$*§¶

2881.86 ± 705.12*#§¶

HV (mm3)

7525.44 ± 868.22#$

7496.65 ± 850.02#$

7348.78 ± 1118.41#$

6751.96 ± 1053.22$*§¶

5876.33 ± 907.72*#§¶

237.47 ± 25.67#$¶

148.76 ± 26.05*#$§

233.32 ± 26.60#$¶

139.43 ± 24.82$*§¶

125.50 ± 21.18*#§¶

CSF P-tau (pg/mL)

27.79 ± 11.87

39.43 ± 23.44

25.62 ± 11.83

48.82 ± 24.92

62.29 ± 35.07*#§¶

CSF T-tau (pg/mL)

59.43 ± 24.64#$¶

75.69 ± 39.54*#$§

54.91 ± 22.63#$¶

102.51 ± 55.31$*§¶

127.99 ± 72.73*#§¶

Plasma NFL (pg/mL)

31.99 ± 24.58#$

36.19 ± 13.93$

33.92 ± 20.38#$

40.14 ± 19.50§*

46.78 ± 19.20*§¶

Cognitive scores

*#$

*#$

#$§¶

Brain structure

Baseline Biomarkers
CSF Aβ (pg/mL)

#$¶

*#$§

#$¶

$*§¶

Values are n (%) or mean ± SD.
CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s disease; − or +, without or with β-Amyloid; MMSE,
Mini-Mental State Examination; CDRSB, Clinical Dementia Rating Sum of Boxes; ADAS-cog 11, Alzheimer’s Disease Assessment
Scale 11; ADAS-cog 13, Alzheimer's Disease Assessment Scale 13; EC, entorhinal cortex; HV, hippocampal volume; CSF,
cerebrospinal fluid; Aβ, β-amyloid; P-tau, phosphorylated-tau; T-tau, total tau; NFL, neurofilament light.
*, significantly different from MCI−; #, significantly different from MCI+; $, significantly different from AD+; §, significantly
different from CN−; ¶, significantly different from CN+.

p < 0.001), higher CSF T-tau (β = 0.254, p < 0.001),
worse performances on MMSE (β = −0.228,
p < 0.001), ADAS-cog 11 (β = 0.315, p < 0.001),
ADAS-cog 13 (β = 0.340, p < 0.001) and CDRSB
(β = 0.234, p < 0.001), smaller hippocampal volume
(β = −0.388, p < 0.001), and thinner EC thickness
(β = −0.272, p < 0.001).

and MCI− (p = 0.014) groups. Longitudinally,
plasma NFL markedly increased in the five groups
(all p < 0.001) with the highest change rate in the
AD+ group (Fig. 1; Table 2).

3.1 Baseline concentration and annual change
of plasma NFL

Without taking diagnostic categories into consideration, rate of change in plasma NFL highly
significantly correlated with all cognitive scales
(estimate = −0.79, p < 0.001 for MMSE; estimate =
0.74, p < 0.001 for CDRSB; estimate = 1.75, p <
0.001 for ADAS-cog 11; and estimate = 2.01, p <
0.001 for ADAS-cog 13) and brain structure
(estimate = −91.84, p = 0.003 for EC thickness and

Baseline levels of plasma NFL were significantly
higher in the AD+ group than in the CN−
(p < 0.001), CN+ (p = 0.003), and MCI− (p < 0.001)
groups, but not than in the MCI+ group (p = 0.065)
(Fig. 1; Table 1). Levels were also higher in the
MCI+ compared with that in the CN− (p < 0.001)

http://bsa.tsinghuajournals.com

3.2 Rate of change in plasma NFL and
longitudinal changes in CSF biomarkers,
cognition and brain structure
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p = 0.037), CDRSB score (estimate = 0.29, p = 0.034),
ADAS-cog 11 (estimate = 1.01, p = 0.032), and EC
thickness (estimate = −232.60, p = 0.003); for the
MCI− group and CDRSB score (estimate = 0.71,
p < 0.001), ADAS-cog 13 (estimate = 1.34, p = 0.023),
and HV (estimate = −121.70, p = 0.024); for MCI+
group and MMSE (estimate = −1.32, p < 0.001),
CDRSB (estimate = 1.02, p < 0.001), ADAS-cog 11
(estimate = 2.50, p < 0.001), ADAS-cog 13
(estimate = 3.03, p < 0.001), EC thickness
(estimate = −118.20, p = 0.002), and HV (estimate =
−138.10, p = 0.002); as well as for the AD+ group
and CDRSB score (estimate = 2.74, p = 0.004) and
ADAS-cog 13 (estimate = 7.03, p = 0.038; Table S1).

Fig. 1

Baseline concentration (A) and estimated within-person

annual change (B) in plasma NFL. A, different from CN− group; B,
different from CN+ group; C, different from MCI− group; D, different
from AD+ group; E, different from MCI− group; *, significantly
different from zero. Abbreviations: CN, cognitively normal; MCI, mild
cognitive impairment; AD, Alzheimer’s disease; − or +, without or
with β-Amyloid.

estimate = −92.22, p = 0.003 for HV) other than
CSF biomarkers (Table 3). Moreover, statistically
significant longitudinal correlations were found
for the CN− group and MMSE (estimate = −0.40,

3.3 Plasma NFL in quartiles and risk of CN-toprodromal AD conversion
Compared with the lowest quartile of baseline
plasma NFL, the highest quartile was associated
with a 4.72-fold increased risk of CN-to-prodromal
AD conversion (95% confidence interval, CI =
1.55−14.41; Table S2 and Fig. S1). The risk was quite
smaller after additional adjustment for APOE
ε4 (hazard ratio, HR, 3.92; 95% CI = 1.29−11.87).
The second and the third quartiles of plasma NFL
were not associated with increased risk. However,

Table 2 Estimated with-person annual change of parameters over time
Characteristics

CN−

CN+

MCI−

MCI+

AD+

Number of
participants

178

113

168

290

86

Plasma NFL (pg/mL)

1.86(0.89, 2.83)

p value

< 0.001

*#$¶

3.10 (1.75, 4.46)
< 0.001

1.94 (0.92, 2.98)
< 0.001

*#$§

#$§¶

3.73 (2.93, 4.55)
< 0.001

*$§¶

6.04 (2.75, 9.33)
< 0.001*#§¶

CSF Biomarkers
CSF Aβ (pg/mL)

−3.11 (−5.24, −0.98)

−1.36 (−4.07, 1.30)

−1.78 (−4.03, 0.49)

−2.41 (−4.06, −0.78)

−1.34 (−6.48, 3.97)

p value

0.004

0.309

0.125

0.006

0.620

CSF P-tau (pg/mL)

2.06 (0.49, 3.65)

3.91 (2.12, 5.70)

2.48 (0.60, 4.29)

3.22 (1.92, 4.49)

2.15 (-2.02, 6.29)

$

p value

0.012

< 0.001

0.010

< 0.001

0.312

CSF T-tau (pg/mL)

−0.27 (−2.33, 1.83)

1.60 (−0.82, 4.03)

0.34 (−2.02, 2.74)

1.47 (−0.21, 3.17)

7.95 (2.67, 13.36)

p value

0.794

0.192

0.777

0.084

0.004

Values are mean with 95% confidence interval; Bold fonts represent statistically significant. *, significantly different from MCI−; #,
significantly different from MCI+; $, significantly different from AD+; §, significantly different from CN−; ¶, significantly different
from CN+. CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s disease; − or +, without or with β-Amyloid;
NFL, neurofilament light; CSF, cerebrospinal fluid; Aβ, β-Amyloid; P-tau, phosphorylated-tau; T-tau, total tau.
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Table 3 Correlations between log-transformed rate of change
in plasma NFL and longitudinal changes in biochemical markers
Estimate

p value

−0.53

0.824

CSF P-tau

2.69

0.198

CSF T-tau

2.55

0.310

MMSE

−0.79

< 0.001

CDRSB

0.74

< 0.001

ADAS-cog 11

1.75

< 0.001

ADAS-cog 13

2.01

< 0.001

EC thickness

−91.84

0.003

HV

−92.22

0.003

CSF Aβ

Bold fonts represent statistically significant. CSF, cerebrospinal
fluid; Aβ, β-Amyloid; P-tau, phosphorylated-tau; T-tau, total
tau; MMSE, Mini-Mental State Examination; CDRSB, Clinical
Dementia Rating Sum of Boxes; ADAS-cog 11, Alzheimer’s
Disease Assessment Scale 11; ADAS-cog 13, Alzheimer’s Disease
Assessment Scale 13; EC, entorhinal cortex; HV, hippocampal
volume.

we failed to detect any correlations between
the rate of change in NFL quartiles and the risk
of CN-to-prodromal AD conversion.
3.4 Plasma NFL in quartiles and risk of MCIto-AD conversion
Elevated plasma NFL levels were associated
with increased risk of MCI-to-AD conversion
(quartile 1 vs. 4: HR, 6.64; 95% CI = 2.22–19.83;
quartile 2 vs. 4: HR, 5.81; 95% CI = 1.97−17.15;
Table 4 and Fig. 2). After additional adjustment
for APOE ε4, this association was still significant
for quartile 1 vs. 4 (HR, 6.45; 95% CI = 2.07−20.11)
and quartile 2 vs. 4 (HR, 6.08; 95% CI = 2.03−18.17).
The highest quartile of rate of change in plasma
NFL was associated with a 5.60-fold increased
risk of AD (95% CI = 1.94−16.21) compared with
the bottom quartile after adjusting for age, sex,
and education (Table 4; Fig. 2). This association
remained significant after additional adjustment
for APOE ε4 (HR, 5.41; 95% CI = 1.83−16.01).
However, after adjustment for APOE ε4, the
association of the second quartile compared with
the lowest quartile was not significant (before

http://bsa.tsinghuajournals.com

adjustment HR, 3.65; 95% CI = 1.28−10.42; after
adjustment HR, 2.39; 95% CI = 0.83−6.92).
3.5 The effects of plasma NFL on diagnostic
accuracy
Baseline plasma NFL was differentiated between
the AD dementia group and controls, with an
AUROC of 0.841 (Fig. S2). However, the rate of
change in plasma NFL had an AUROC of 0.806.
By comparison, the AUROCs ranged from 0.875
to 0.922 for CSF P-tau, T-tau, and Aβ. These
AUROCs were corrected for age, sex, educational
level, and APOE ε4 genotype.

4 Discussion
We discovered that baseline plasma NFL concentration was significantly higher in the AD Aβ+
group and it markedly increased longitudinally.
We also corroborated that higher rates of change
in plasma NFL (1) were correlated with cognitive
deficits and neuroimaging hallmarks of AD over
time, (2) were strongly associated with the risk of
MCI-to-AD conversion, and (3) had diagnostic
accuracy for AD dementia in the same range as
established CSF biomarkers.
Plasma NFL markedly increased in all of the
five groups with the highest rate of change in
the AD Aβ+ group, which implied that plasma
NFL increment was a cumulative effect of
neurodegeneration and it occurs throughout the
process. Our study also discovered that both of
the baseline concentration and rate of change in
plasma NFL correlated with several cognitive and
imaging AD hallmarks at baseline and over
time. In detail, plasma NFL was associated with
general cognition (MMSE, ADAS-cog and CDRSB
scores) at baseline as well as with decline over
time. For imaging measures, associations of
NFL were identified with EC thickness and
hippocampal volume. The rate of change in NFL
had more significant correlations with all the
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Table 4 Baseline and rate of change in plasma NFL in quartiles and risk of MCI-to-AD conversion
Baseline log plasma NFL
Model 1a

Log-transformed rate of change in plasma NFL

Model 2b

Model 1a

Model 2b

Quartiles of plasma NFL

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

The first quartile

6.64(2.22,19.83)

0.001

6.45(2.07,20.11)

0.001

5.60(1.94,16.21)

0.001

5.41(1.83,16.01)

0.002

The second quartile

5.81(1.97,17.15)

0.001

6.08(2.03,18.17)

0.001

3.65(1.28,10.42)

0.015

2.39(0.83,6.92)

0.107

The third quartile

1.86(0.63,5.44)

0.260

2.10(0.70,6.36)

0.188

1.98(0.65,6.00)

0.229

1.66(0.55,4.97)

0.316

The bottom quartile

Ref.

0.001

Ref.

0.003

Ref.

0.008

Ref.

0.011

Model 1 with age, sex and educational level as covariates.
Model 2 with age, sex, educational level and APOE ε4 status as covariates.
Abbreviations: NFL, neurofilament light; HR, hazard ratio; CI, confidence interval.
Bold fonts represent statistically significant.
a

b

Fig. 2

Kaplan-Meier survival curves for probability of MCI conversion to AD according to the four quartiles of plasma NFL. (A)

Quartiles of log-transformed baseline NFL concentration. (B) Quartiles of log-transformed rate of change in NFL concentration. Number of
individuals at risk at each time interval are shown below the two graphs. Log-rank (Mantel-Cox) p values are depicted at the top right
corner of each graph.

measures except hippocampal volume, compared
with baseline level of NFL, suggesting that
longitudinal change might be a better predictor
of cognitive decline and brain atrophy related
with AD. More significant correlations were
detected in the MCI Aβ+ and AD Aβ+ groups,
especially for the cognitive scales. This result
was in line with the recently published opinion
that plasma NFL correlated with cognitive decline
and brain atrophy, which was independent of Aβ
pathology [21]. The baseline associations with
CSF biomarkers (CSF Aβ, P-tau, and T-tau levels)
replicated previous findings, which showed that

baseline plasma NFL correlated with lower CSF
Aβ, elevated CSF P-tau and higher CSF T-tau
levels in the whole cohort [16]. However, we
failed to observe significant correlations of plasma
NFL with CSF biomarkers for AD pathology
longitudinally. No positive relationship between
NFL rate of change and the rate of change in CSF
core biomarkers for AD were investigated in our
study. This finding probably reflects the notion
that several different pathologic conditions are
present in AD (e.g., Aβ, tau, and degeneration
of different types of axons) and drive different
biomarker responses, which will be weakly
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correlated overall. As we all know, the pathological
processes in AD begin more than two decades
before the onset of clinical symptoms. The
correlations might be confounded by clinical
diagnosis owing to that each single clinical stage
has special pathological changes. This result
may also indicate that NFL changes in the blood
most closely reflect clinical phenotypes rather
than pathological phenotypes of AD. Moreover,
future longitudinal studies with longer follow-up
duration are in command to clarify the true
underlying associations.
Previous studies showed that higher CSF NFL
levels were associated with higher risk of MCI
among cognitively intact individuals [22] and a
shorter survival among patients with AD dementia
[23], suggesting that CSF NFL is a marker of
clinical progression. We are the first to find
that NFL in plasma could also predict disease
progression by showing that both higher baseline
plasma NFL level and elevated change rate are
also strongly associated with risk of MCI-to-AD
conversion and higher baseline plasma NFL level
could also predict CN-to-prodromal AD conversion. The result showed that both CSF and
peripheral NFL were predictors of disease progression. However, the predicting efficacy of the
two biomarkers needs to be compared based on
high-quality sample with long follow-up duration.
In agreement with recently published studies
on sporadic AD [11, 16, 24] and familial AD [25]
we found increased plasma NFL concentrations
in AD+ patients as well as in MCI subjects compared with non-demented controls. The results
of the current study confirm those reported by
Mattsson et al. in terms of the NFL performance
as a potential plasma diagnostic test [16]. In both
studies, almost identical areas under the ROC
curves, contrasting AD patients versus nondemented controls, were obtained (0.84 and 0.87,
respectively). Furthermore, we also detected the
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potential diagnostic accuracy of the rate of change
in plasma NFL, which was shown to have an
AUROC of 0.806. To our knowledge, it is the first
time that a peripheral, noninvasive biomarker for
neurodegeneration showed diagnostic accuracy
for AD dementia compared with established CSF
biomarkers.
Taken together, these findings support that
plasma NFL is a promising biomarker for neurodegeneration in AD, which may have potential for
prognosis and monitoring of disease progression.
However, increased plasma NFL concentration
has also been found in several other neurodegenerative disorders, such as progressive
supranuclear palsy [26], frontotemporal dementia
[13], Huntington's disease [12], Parkinson’s disease
[27], and human immunodeficiency virus with
brain engagement [28], implying that it lacks
disease specificity for AD. Therefore, we do not
envision that plasma NFL can be used as a tool to
differentiate AD from other neurodegenerative
diseases. Rather, it may be valuable as a general
biomarker for neurodegeneration.
Our analysis is a longitudinal analysis of plasma
NFL data, including the calculation of the change
rate of NFL, the correlation of the rate of change
in NFL with cognition and brain structure, the
effect of the rate of change in NFL in the diagnosis
of AD from controls, and the predictive value in
disease progression, all of which makes the
value of plasma NFL more comprehensive in the
diagnosis and prognosis of AD. However, it still
requires high-quality research with large samples
to replicate the results. Perhaps the most important
limitation of our study is the relatively small,
age-unmatched groups, which we tried to counterbalance by controlling for age in all statistical
analyses. Secondly, when divided into five groups,
the small sample may limit statistical power to
detect longitudinal changes, especially in the
preclinical and early symptomatic AD groups.
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A larger age span should also be included in
future work because it is possible that vascular
comorbidities may change with age and alter the
diagnostic accuracy of plasma NFL for patients
with AD vs. controls.

5 Conclusion
Taken together, our findings suggest that plasma
NFL is a valuable biomarker of neurodegeneration
but not specific for AD pathobiology. We speculate
that plasma NFL will not be able to replace the
CSF biomarkers of neurodegeneration within a
given diagnostic group, but it could perhaps be
considered as a potential convenient longitudinal
screening tool.
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